1. 440 Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer. (10th December 2020) Authors: Sun, Guo Gui; Jia, Jing Hao; Gao, Peng; Yao, Xue Min; Chen, Ming Da; Yao, Wei Nan; Sun, Lu; Wang, Wei Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗